MA37672A1 - Formulation d'agoniste des récepteurs à la somatostatine - Google Patents

Formulation d'agoniste des récepteurs à la somatostatine

Info

Publication number
MA37672A1
MA37672A1 MA37672A MA37672A MA37672A1 MA 37672 A1 MA37672 A1 MA 37672A1 MA 37672 A MA37672 A MA 37672A MA 37672 A MA37672 A MA 37672A MA 37672 A1 MA37672 A1 MA 37672A1
Authority
MA
Morocco
Prior art keywords
weight
forming
somatostatin receptor
compositions
receptor agonist
Prior art date
Application number
MA37672A
Other languages
English (en)
French (fr)
Inventor
Catalin Nistor
Markus Johnsson
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49623188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37672(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/059917 external-priority patent/WO2012160213A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MA37672A1 publication Critical patent/MA37672A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA37672A 2012-05-25 2013-05-24 Formulation d'agoniste des récepteurs à la somatostatine MA37672A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/059917 WO2012160213A1 (en) 2011-05-25 2012-05-25 Controlled release peptide formulations
US201261730613P 2012-11-28 2012-11-28
PCT/EP2013/060739 WO2013174978A1 (en) 2012-05-25 2013-05-24 Somatostatin receptor agonist formulations

Publications (1)

Publication Number Publication Date
MA37672A1 true MA37672A1 (fr) 2016-07-29

Family

ID=49623188

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37672A MA37672A1 (fr) 2012-05-25 2013-05-24 Formulation d'agoniste des récepteurs à la somatostatine

Country Status (23)

Country Link
US (2) US11672843B2 (enExample)
JP (1) JP6374380B2 (enExample)
KR (1) KR102139080B1 (enExample)
CN (1) CN104487050B (enExample)
AU (1) AU2013265210B2 (enExample)
BR (1) BR112014029425A2 (enExample)
CA (1) CA2874367C (enExample)
CL (1) CL2014003185A1 (enExample)
CO (1) CO7160067A2 (enExample)
DK (1) DK2861209T3 (enExample)
EA (1) EA035495B1 (enExample)
ES (1) ES2834318T3 (enExample)
HK (1) HK1207985A1 (enExample)
IL (1) IL235740A0 (enExample)
IN (1) IN2014DN09831A (enExample)
MA (1) MA37672A1 (enExample)
MX (1) MX350964B (enExample)
NZ (1) NZ702028A (enExample)
PE (1) PE20150195A1 (enExample)
PH (1) PH12014502614A1 (enExample)
SG (1) SG11201407678YA (enExample)
TN (1) TN2014000483A1 (enExample)
WO (1) WO2013174978A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG173326A1 (en) * 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
KR102066755B1 (ko) * 2011-05-25 2020-01-15 카무러스 에이비 조절 방출형 펩티드 제형
WO2018060212A1 (en) * 2016-09-27 2018-04-05 Camurus Ab Mixtures and formulations comprising an alkyl ammonium edta salt
CN113018248B (zh) * 2019-12-23 2022-07-22 南京清普生物科技有限公司 一种缓释递药系统
CN114240934B (zh) * 2022-02-21 2022-05-10 深圳大学 一种基于肢端肥大症的图像数据分析方法及系统

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
CA2535463A1 (en) 1989-07-07 1991-01-08 Novartis Ag Octreotide-pamoate and its use in sustained release formulations of water soluble peptides
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
AU2699892A (en) 1991-10-04 1993-05-03 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
WO1995026715A2 (en) 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
CA2231273A1 (en) 1995-10-12 1997-04-17 Lise Sylvest Nielsen A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
EP0975331A1 (en) 1997-04-17 2000-02-02 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SI1140148T1 (sl) 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
JP5180474B2 (ja) 2003-08-04 2013-04-10 カムルス エービー 両親媒性粒子の特性を改良する方法
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
ES2623881T3 (es) 2003-11-07 2017-07-12 Camurus Ab Composiciones de lípidos y péptidos catiónicos
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
JP4966018B2 (ja) 2004-01-23 2012-07-04 カムルス エービー 三元非ラメラ脂質組成物
SG173326A1 (en) * 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
PL1778187T3 (pl) 2004-08-04 2012-09-28 Camurus Ab Kompozycje tworzące nielamelarne dyspersje
KR100983746B1 (ko) * 2005-01-14 2010-09-24 카무러스 에이비 소마토스타틴 유사 제형
DE602005026998D1 (de) 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
EP1848403B8 (en) 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
US9060935B2 (en) * 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
JP5721624B2 (ja) 2008-07-08 2015-05-20 ノバルティス アーゲー 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
KR102066755B1 (ko) * 2011-05-25 2020-01-15 카무러스 에이비 조절 방출형 펩티드 제형
AU2012348640B2 (en) * 2011-12-05 2016-07-21 Camurus Ab Robust controlled-release peptide formulations

Also Published As

Publication number Publication date
JP6374380B2 (ja) 2018-08-15
SG11201407678YA (en) 2014-12-30
ES2834318T3 (es) 2021-06-17
IL235740A0 (en) 2015-01-29
KR20150016977A (ko) 2015-02-13
BR112014029425A2 (pt) 2017-06-27
DK2861209T3 (da) 2020-12-21
CA2874367A1 (en) 2013-11-28
CN104487050B (zh) 2019-08-20
AU2013265210A1 (en) 2014-12-04
US20230372436A1 (en) 2023-11-23
CO7160067A2 (es) 2015-01-15
NZ702028A (en) 2016-07-29
CA2874367C (en) 2020-08-18
MX2014014379A (es) 2015-02-05
JP2015520762A (ja) 2015-07-23
EA201491928A1 (ru) 2015-09-30
PH12014502614A1 (en) 2015-01-21
CL2014003185A1 (es) 2015-04-24
EA035495B1 (ru) 2020-06-25
MX350964B (es) 2017-09-27
PE20150195A1 (es) 2015-02-27
CN104487050A (zh) 2015-04-01
US11672843B2 (en) 2023-06-13
IN2014DN09831A (enExample) 2015-08-07
KR102139080B1 (ko) 2020-07-29
WO2013174978A1 (en) 2013-11-28
US20150105332A1 (en) 2015-04-16
TN2014000483A1 (en) 2016-03-30
AU2013265210B2 (en) 2016-09-15
HK1207985A1 (en) 2016-02-19

Similar Documents

Publication Publication Date Title
MA37672A1 (fr) Formulation d'agoniste des récepteurs à la somatostatine
AR060784A1 (es) Mezclas binarias de acido hialuronico y su uso terapeutico
BR112015004871A2 (pt) composição para formação de revestimento sólido e junta tubular rosqueada
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
MA38698A1 (fr) Système d'administration transdermique
SV2005002044A (es) Solidos supersaturados estabilizados de drogas lipofilicas ref. p-sv-77.892/gh
FR3067930B1 (fr) Dispersions comprenant au moins une huile volatile hydrocarbonee
MX345256B (es) Formulaciones estables para inyeccion parenteral de farmacos de molecula pequeña.
AR089673A1 (es) Formulacion de premezcla de dexmedetomidina
EA201491005A1 (ru) Устойчивые составы с контролируемым высвобождением
EA201491685A1 (ru) Препарат для инъекций
AR033221A1 (es) Composicion farmaceutica finamente autoemulsionable
BR112012023455A2 (pt) composição de material, preparação e uso da mesma
BR112013030104A8 (pt) Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit
FR2999924B1 (fr) Association d'actifs comprenant au moins une huile essentielle, une cyclodextrine et un corps gras liquide et composition la contenant.
CO6602159A2 (es) Formulaciones de aceite que comprenden compuestos de ciclopropeno
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
EA201171407A1 (ru) Способ и композиция для борьбы с эктопаразитами
MX2021003766A (es) Formulaciones de anticuerpos anti-fgfr2.
CY1109430T1 (el) Υγρη συνθεση περιλαμβανουσα αργινινη και α-λιποϊκο οξυ και χρηση αυτης για βελτιωση της σεξουαλικης λειτουργιας
Evans et al. Binding of local anaesthetics to the lipid emulsion Clinoleic™ 20%
ATE489100T1 (de) Gleitmittelzubereitung
ATE450241T1 (de) Dünnflüssige w/o emulsionen
FR3049868B1 (fr) Produit permettant la formation d'un implant therapeutique dans le corps d'un sujet - implant et composition associes
FR2999923B1 (fr) Composition cosmetique aqueuse comprenant de l'alkylcellulose, une huile non volatile et un corps gras solide.